David W. Boyer sold $241k of NBIX
Chief Corp. Affairs Officer at NEUROCRINE BIOSCIENCES INC. 1,811 shares at an average of $133.07, traded Feb 13, 2024, filed Feb 15, 2024.
Score components
- +15RoleOfficer
- +13Trade size$241k at market
- +10Share of holdings soldSold 27% of holdings
- +15Cluster12 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000914475-24-000069, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2024 | SOpen-market sale Common Stock10b5-1 | -955 | $133.10 | $127k | 5,751 | Feb 15, 2024 |
| Feb 13, 2024 | SOpen-market sale Common Stock10b5-1 | -856 | $133.05 | $114k | 4,895 | Feb 15, 2024 |
| Feb 13, 2024 | AGrant or award Stock Optionderivative10b5-1 | +30,977 | $0.00 | $0 | 30,977 | Feb 15, 2024 |
| Feb 13, 2024 | AGrant or award Restricted Stock Unitderivative10b5-1 | +6,165 | $0.00 | $0 | 6,165 | Feb 15, 2024 |
Related signals
Other insiders at NEUROCRINE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $363k 2,311 shares | -5% | |
| 21Weak | NEUROCRINE BIOSCIENCES INC | David W. Boyer Chief Corp. Affairs Officer | $130k 826 shares | -9% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $333k 2,154 shares | -3% | |
| 3Weak | NEUROCRINE BIOSCIENCES INC | Leslie Norwalk V director | $228k 1,250 shares | -44% | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $791k 4,367 shares | -21% | |
| 18Weak | NEUROCRINE BIOSCIENCES INC | Darin Lippoldt Chief Legal Officer | $1.8M 10,000 shares | -15% | |
| 33Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $2.6M 14,571 shares | -74% | |
| 18Weak | NEUROCRINE BIOSCIENCES INC | Darin Lippoldt Chief Legal Officer | $1.7M 10,000 shares | -18% | |
| 40Moderate | NEUROCRINE BIOSCIENCES INC | Stephen A Sherwin director | $4.1M 25,000 shares | -61% | |
| 32Weak | NEUROCRINE BIOSCIENCES INC | Leslie Norwalk V director | $210k 1,250 shares | -31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.